검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Treatment with immune checkpoint inhibitors. (Treatment with immune checkpoint inhibitors.) Inge Marie Svane·Cancer ORR 2% |
|---|---|
Overview Program | Treatment with immune checkpoint inhibitors. |
Overview Company | Inge Marie Svane |
Overview Modality | ANTIBODY |
Overview Target | Cancer |
Overview Indication | Cancer; Metastatic Cancer |
Overview Phase | PRECLINICAL |
Overview Status | ACTIVE |
MoA Mechanism | targeted and targeted liquid chromatography-tandem mass spectrometry-based metabolomics, CD8 + T-cell depletion, receptor |
MoA Biomarker | biomarker of inflammation and tissue remodeling and has now emerged as a pseudoenzymatic immune checkpoint |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Post-Marketing Surveillance of the Safety and Effectiveness of Cabozantinib in Japanese Patients With Advanced Renal Cell Carcinoma.. This post-marketing surveillance study evaluated the real-world safety and effectiveness of cabozantinib in Japanese patients with advanced renal cell carcinoma (aRCC). This prospective, observational study enrolled patients with histologically or cytologically conf… |
Clinical Primary efficacy | ORR 2% |
Clinical ORR | 2% |
Clinical OS | 227 |
Clinical Result source | ClinicalTrials.gov NCT03296137 |
Clinical Data Tier / Score | A · 26 |
Clinical Program phase | PRECLINICAL |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Treatment with immune checkpoint inhibitors. (Treatment with immune checkpoint inhibitors.) Inge Marie Svane·Cancer ORR 2% |
|---|---|
Overview Program | Treatment with immune checkpoint inhibitors. |
Overview Company | Inge Marie Svane |
Overview Modality | ANTIBODY |
Overview Target | Cancer |
Overview Indication | Cancer; Metastatic Cancer |
Overview Phase | PRECLINICAL |
Overview Status | ACTIVE |
MoA Mechanism | targeted and targeted liquid chromatography-tandem mass spectrometry-based metabolomics, CD8 + T-cell depletion, receptor |
MoA Biomarker | biomarker of inflammation and tissue remodeling and has now emerged as a pseudoenzymatic immune checkpoint |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Post-Marketing Surveillance of the Safety and Effectiveness of Cabozantinib in Japanese Patients With Advanced Renal Cell Carcinoma.. This post-marketing surveillance study evaluated the real-world safety and effectiveness of cabozantinib in Japanese patients with advanced renal cell carcinoma (aRCC). This prospective, observational study enrolled patients with histologically or cytologically conf… |
Clinical Primary efficacy | ORR 2% |
Clinical ORR | 2% |
Clinical OS | 227 |
Clinical Result source | ClinicalTrials.gov NCT03296137 |
Clinical Data Tier / Score | A · 26 |
Clinical Program phase | PRECLINICAL |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
추천 비교
추천 비교